Skip to main content

Aptose Biosciences, Inc. (APTO)

NASDAQ: APTO · Delayed Price · USD
2.09
0.01 (0.48%)
At close: Dec 8, 2021 4:00 PM
2.08
-0.01 (-0.43%)
After-hours:Dec 8, 2021 5:35 PM EST
Market Cap185.90M
Revenue (ttm)n/a
Net Income (ttm)-55.74M
Shares Out88.95M
EPS (ttm)-0.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume428,953
Open2.08
Previous Close2.08
Day's Range2.06 - 2.15
52-Week Range1.96 - 7.20
Beta1.25
AnalystsStrong Buy
Price Target11.29 (+440.2%)
Earnings DateNov 11, 2021

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the t...

IndustryBiotechnology
Founded1986
CEOWilliam Rice
Employees39
Stock ExchangeNASDAQ
Ticker SymbolAPTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is 11.29, which is an increase of 440.19% from the latest price.

Price Target
$11.29
(440.19% upside)
Analyst Consensus: Strong Buy

News

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting Luxeptinib clinical update in AML and B-cell cancers

1 week ago - GlobeNewsWire

Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options

Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...

2 weeks ago - GlobeNewsWire

Aptose Reports Results for the Third Quarter 2021

- Conference call and webcast at 5:00 pm ET today -

3 weeks ago - GlobeNewsWire

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for ...

1 month ago - GlobeNewsWire

Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome ...

HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients

1 month ago - GlobeNewsWire

Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021

SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...

1 month ago - GlobeNewsWire

Aptose Expands Senior Leadership Team

Janet Clennett, CPA, appointed Vice President, Finance

1 month ago - GlobeNewsWire

Aptose to Present at September Investor Conferences

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...

3 months ago - GlobeNewsWire

Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the Upgrade

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es...

4 months ago - Zacks Investment Research

Aptose Reports Results for the Second Quarter 2021

- Conference call and webcast at 5:00 pm EDT today -

4 months ago - GlobeNewsWire

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...

4 months ago - GlobeNewsWire

Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress

Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or ref...

5 months ago - Benzinga

Aptose Presents Highlights from EHA During Corporate Update Event

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...

5 months ago - GlobeNewsWire

Biotech Penny Stocks To Watch For June 2021

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:FBIOMBIORGLS
6 months ago - PennyStocks

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...

6 months ago - GlobeNewsWire

Aptose to Hold Corporate Update Friday, June 11th

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS

6 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Aptose to Present at Upcoming Investor Conferences

SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyin...

6 months ago - GlobeNewsWire

Aptose Reports Results for the First Quarter 2021

- Conference call and webcast at 4:30 pm EDT today -

7 months ago - GlobeNewsWire

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...

7 months ago - GlobeNewsWire

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...

8 months ago - GlobeNewsWire

Aptose Biosciences Stock Trades Higher After Q4 Earnings: Technical Levels To Watch

Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday.  The stock gained 66.21% in Wednesday's regular session, closing at $6.10.

8 months ago - Benzinga

Why Aptose Biosciences Stock Is Skyrocketing Today

The company reported very encouraging results from an early-stage study.

8 months ago - The Motley Fool